New US bill aims to alter first-filer measure for drug firms
This article was originally published in SRA
Executive Summary
US lawmakers have introduced yet another bill in Congress to try to stop so-called pay-for-delay settlement agreements between brand-name pharmaceutical companies and generic drug makers1,2.